SCHEMBL6348194

SCHEMBL6348194

COc1ccc(C(=O)N2C=C(c3ccccc3)N(CC(=O)O)C(=O)C2C(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
PDPK1 O15530 1/20 0.39
SIRT3 Q9NTG7 1/20 0.38
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ELANE P08246 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
F2 P00734 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
P2RX3 P56373 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6348196 1.00 NPC1 (0.40) NPC1PDPK1SIRT3ALDH1A1SMN1; SMN2
SCHEMBL6348102 0.90 CA12 (0.36) ALDH1A1KMT2APOLB
SCHEMBL6348100 0.90 CA12 (0.36) ALDH1A1KMT2APOLB
SCHEMBL6349771 0.90 CA12 (0.36) ALDH1A1KMT2APOLB
SCHEMBL6347245 0.89 RECQL (0.43) ALDH1A1KMT2ARECQL
SCHEMBL6347247 0.89 RECQL (0.43) ALDH1A1KMT2ARECQL
SCHEMBL6346925 0.87 MDM2 (0.38) PDPK1SIRT3ALDH1A1SMN1; SMN2CA1
SCHEMBL6346920 0.87 MDM2 (0.38) PDPK1SIRT3ALDH1A1SMN1; SMN2CA1
SCHEMBL6355704 0.85 PKM (0.38) ALDH1A1SMN1; SMN2CYP1A2CYP2C9HPGD
SCHEMBL6357399 0.85 PKM (0.38) ALDH1A1SMN1; SMN2CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 NPC1 2985/4885PDPK1 3110/4885SIRT3 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.